Kitov Pharma Ltd.

NASDAQ: KTOVHealthcare / Biotechnology / Israel
0.8700+0.0200+2.35%Vol 153 9761Y Perf -67.41%
Jun 24th, 2019 15:43
BID0.8700 ASK0.8900
Open0.8400 Previous Close0.8500
Pre-Market- After-Trading0.89
 - -%  0.02 2.30%
Target Price
12.00 
Analyst Rating
Strong Buy 1.00
Potencial %
1 279.31 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
 —    -
Market Cap (mil)14 
Earnings Rating
Neutral
Price Range Ratio 52wk %
13.14 
Earnings Date
4th Mar 2019

Today's Price Range

0.84000.9100

52wk Range

0.56002.92

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Month
-15.84%
3 Months
-24.78%
6 Months
14.86%
1 Year
-67.41%
3 Years
-78.15%
5 Years
-

Name / TickerPriceChg.Chg.%
KTOV0.87000.02002.35
AAPL198.58-0.2000-0.10
GOOG1 115.52-6.3600-0.57
MSFT137.780.81000.59
XOM76.95-0.7400-0.95
WFC46.27-0.6200-1.32
JNJ143.060.97000.68
FB192.601.46000.76
GE10.28-0.2000-1.91
JPM108.66-0.7800-0.71
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
3/2019 QR-0.190.00-
6/2019 QR-0.060.00-
12/2019 FY-0.460.00-
12/2020 FY-0.230.00-
Next Report Date-
Estimated EPS Next Report-
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume153 976
Shares Outstanding (in ths.)15 758
Trades Count104
Dollar Volume134 032
Avg. Volume1 404 615
Avg. Weekly Volume82 162
Avg. Monthly Volume93 925
Avg. Quarterly Volume528 081
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Kitov Pharma Ltd.

Kitov Pharma Ltd is development stage biopharmaceutical company. It focuses on the development of KIT-302, a combination drug for the simultaneous treatment of two clinical conditions pain caused by osteoarthritis and hypertension; and NT219 which is a fixed-dose combination of two drug products that treat osteoarthritis pain and hypertension simultaneously. The company operates its business in Israel.

CEO: Isaac Israel

Teplephone: +972 39333121

Address: 132 Menachem Begin Road, Tel Aviv 6701101, , ISR

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

54%46%

News